The efficacy and changes in blood indicators after taking Pazopanib (Victor) for 2 months

Pazopanib is an oral, small molecule, multi-target tyrosine kinase inhibitor, mainly used to treat renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS). It blocks tumor angiogenesis and cell proliferation by inhibiting signaling pathways such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and c-KIT, thereby delaying tumor growth. Changes in efficacy and blood indicators usually begin to appear about 2 months after patients start taking pazopanib, which is an important reference for evaluating the effectiveness and safety of the drug.

In terms of efficacy, after 2 months of treatment, most patients with renal cell carcinoma or soft tissue sarcoma will experience stable or slightly reduced tumor volume. In some clinical studies, after 2 months of pazopanib treatment, the patient's objective response rate (ORR) can reach 10%-20%, and the disease control rate (DCR) can be as high as 70%-80%. In imaging examinations, CT or MRI scans can show reduced blood supply to the tumor and reduced density of some lesions, which usually indicates that the drug is exerting anti-angiogenic and anti-tumor effects.

In terms of blood indicators, 2 patients may experience certain changes in blood routine after taking the medicine for 2 months. Common hematological reactions include mild to moderate thrombocytopenia, mild decrease in white blood cells or neutrophils, and a small number of patients may develop mild anemia. Most of these changes are controllable and can be managed by regularly monitoring blood counts and adjusting the dose or temporarily discontinuing the drug if necessary. Some patients may also experience an increase in liver function indicators, such as ALT, AST or total bilirubin. Therefore, it is recommended to conduct hematology and liver function monitoring every 2-4 weeks during treatment.

In addition, after taking2 months, patients may experience some non-hematological side effects, such as hand-foot syndrome, fatigue, diarrhea, high blood pressure or decreased appetite. Although these side effects do not directly affect efficacy, they may affect quality of life. Clinical intervention is usually carried out through lifestyle adjustment, drug symptomatic treatment or dose adjustment. Overall, after 2After months of treatment, pazopanib has shown preliminary efficacy in controlling tumor progression. At the same time, monitoring of blood indicators and liver function provides an important guarantee for patients' safe medication.

Reference link:https://www.drugs.com